Remove DEA Remove Epilepsy Remove Medicine Remove Treatment
article thumbnail

And Here We Go Again! NASDAQ Article: Forget Cannabis: Psychedelic Medicine Is the Better Investing Opportunity

Cannabis Law Report

The global march toward cannabis legalization has seemingly awoken another long dormant area of scientific interest: psychedelics as medicine. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to Compass Pathways ‘ psilocybin therapy for treatment-resistant depression.

article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA. will top $1.9

DEA 51
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New U.S. Research Efforts Could Catalyze Medical Cannabis’ Adoption in the Pharmaceutical Industry

Veriheal

The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website. Drug Enforcement Agency (DEA).

article thumbnail

Analysts Envision a $33.2 Billion Medical Cannabis Market By 2027

Veriheal

D espite the Drug Enforcement Agency’s (DEA) announcement in May that it would soon start reviewing grower applications for research purposes, cannabis research continues to be tightly restricted. “(Cannabis is) also used in conjunction with other medicines, either to improve their efficacy or to mitigate negative side effects.

article thumbnail

The Path to Greenlighting CBD

Burns Levinson (Cannabusiness advisory)

This marks the first time in history that the DEA has removed any type of cannabis from Schedule I, and clears the way for the sale of the first non-synthetic, cannabis-derived medicine to win federal approval.

CBD 40
article thumbnail

Navigating Medical Cannabis for Veterans: Benefits and Federal Laws

Veriheal

According to the United States Drug Enforcement Administration (DEA), Schedule One drugs are “drugs with no currently accepted medical use and a high potential for abuse.” 3409), the VA Medicinal Cannabis Research Act of 2018 (H.R. Other substances like heroin and lysergic acid diethylamide also fall under this category.

Law 62
article thumbnail

Approval of Epidiolex Validates What Many CBD Users Already Knew

MedicalJane

The FDA announced in a press release on Monday that it had approved the “first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy.”. Food and Drug Administration (FDA) had approved only three cannabinoid-based medicines. The Next Move Is On The DEA. Prior to this week, the U.S.